Home > Publications database > Post-operative C-reactive protein as a strong independent predictor of long-term colorectal cancer outcomes: consistent findings from two large patient cohorts. > print |
001 | 289463 | ||
005 | 20241228120954.0 | ||
024 | 7 | _ | |a 10.1016/j.esmoop.2024.102982 |2 doi |
024 | 7 | _ | |a pmid:38613909 |2 pmid |
037 | _ | _ | |a DKFZ-2024-00785 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Gwenzi, Tafirenyika |0 P:(DE-He78)35a941418cdcc6c595b7a8a19e355599 |b 0 |e First author |u dkfz |
245 | _ | _ | |a Post-operative C-reactive protein as a strong independent predictor of long-term colorectal cancer outcomes: consistent findings from two large patient cohorts. |
260 | _ | _ | |a London |c 2024 |b BMJ |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1713266232_20788 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
500 | _ | _ | |a #EA:C120#LA:C120#LA:C070# |
520 | _ | _ | |a Post-surgery blood-based biomarkers may be useful for guiding treatment and surveillance decisions among colorectal cancer (CRC) patients. However, most candidate biomarkers provide little if any predictive value beyond stage at diagnosis. We aimed to investigate the independent prognostic value of post-operative serum C-reactive protein (CRP), a highly sensitive biomarker of inflammation, for long-term CRC outcomes in two large patient cohorts.CRP levels were measured from serum samples of CRC patients collected ≥1 month post-surgery in the German DACHS (n = 1416) and the UK Biobank (n = 1149) cohorts. Associations of post-operative CRP with overall survival (OS) and CRC-specific survival (CSS) were assessed using Cox regression and presented as hazard ratios (HRs) with 95% confidence intervals (CIs), adjusted for key sociodemographic and clinical covariates.In both cohorts, consistent strong dose-response relationships between post-operative CRP and both OS and CSS were observed. Adjusted HRs (95% CI) for CRP >10 versus <3 mg/l were 1.93 (1.58-2.35) and 2.70 (2.03-3.59) in the DACHS cohort, and 2.70 (1.96-3.71) and 2.61 (1.83-3.72) in the UK Biobank cohort, respectively. Associations between post-operative CRP and OS were particularly strong among younger patients (<65 years at diagnosis; P value for interaction by age <0.01).Serum CRP determined a month or more after surgery may be useful as a strong independent prognostic biomarker for guiding therapeutic decisions and for surveillance of the course of disease of CRC patients, particularly those <65 years of age at diagnosis. |
536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
650 | _ | 7 | |a C-reactive protein |2 Other |
650 | _ | 7 | |a colorectal |2 Other |
650 | _ | 7 | |a prognosis |2 Other |
650 | _ | 7 | |a survival |2 Other |
650 | _ | 7 | |a systemic inflammation |2 Other |
700 | 1 | _ | |a Schrotz-King, P. |0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86 |b 1 |u dkfz |
700 | 1 | _ | |a Anker, S. C. |b 2 |
700 | 1 | _ | |a Schöttker, B. |0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46 |b 3 |u dkfz |
700 | 1 | _ | |a Hoffmeister, M. |0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |b 4 |u dkfz |
700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 5 |e Last author |u dkfz |
773 | _ | _ | |a 10.1016/j.esmoop.2024.102982 |g Vol. 9, no. 4, p. 102982 - |0 PERI:(DE-600)2844985-X |n 4 |p 102982 |t ESMO open |v 9 |y 2024 |x 2059-7029 |
909 | C | O | |o oai:inrepo02.dkfz.de:289463 |p VDB |p OpenAPC |p openCost |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)35a941418cdcc6c595b7a8a19e355599 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
914 | 1 | _ | |y 2024 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ESMO OPEN : 2022 |d 2023-10-27 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-27 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-27 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-27 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T14:49:18Z |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T14:49:18Z |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-04-12T14:49:18Z |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-27 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-27 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-27 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-27 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-27 |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ESMO OPEN : 2022 |d 2023-10-27 |
915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-27 |
915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-27 |
915 | p | c | |a APC keys set |2 APC |0 PC:(DE-HGF)0000 |
915 | p | c | |a Local Funding |2 APC |0 PC:(DE-HGF)0001 |
915 | p | c | |a DFG OA Publikationskosten |2 APC |0 PC:(DE-HGF)0002 |
915 | p | c | |a DEAL: Elsevier 09/01/2023 |2 APC |0 PC:(DE-HGF)0125 |
915 | p | c | |a DOAJ Journal |2 APC |0 PC:(DE-HGF)0003 |
920 | 2 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 0 |
920 | 2 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 1 |
920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 1 |
920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
920 | 0 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 0 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)C120-20160331 |
980 | _ | _ | |a I:(DE-He78)C070-20160331 |
980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
980 | _ | _ | |a UNRESTRICTED |
980 | _ | _ | |a APC |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|